Benjamin T. Dake, SEE REMARKS at Aerovate Therapeutics, Inc. (AVTE), sold 6,650 shares at $31.97 ($213K) on 2024-04-01, disclosed to the SEC on 2024-04-03.
Scheduled sale ($213k) by SEE REMARKS under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $31.97 | 3,325 | $106K | 50.0% |
| 2 | $31.97 | 3,325 | $106K | 50.0% |
| Total | $31.97 avg | 6,650 | $213K | 100% |
| Filing → |
| AVTE | SELL | 2024-03-27 | $192K | — | Filing → |
| AVTE | SELL | 2024-03-20 | $1.8M | — | Filing → |
| AVTE | SELL | 2023-12-07 | $331K | — | Filing → |